NCT04761198: A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must do a 6-month wash-out period if prior treatment was anti-PD1/PDL-1 therapy

Comments are closed.

Up ↑